Last reviewed · How we verify
NCT03913910
Perianal Fistula Treatment With Autologous Adipose Tissue Injection
trial testing Lipogems in Perianal Fistula in 100 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Azienda Ospedaliero, Universitaria Pisana |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 February 2019 |
| Primary completion | 31 December 2019 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Lipogems
Conditions studied
- Perianal Fistula — all drugs for Perianal Fistula →
Sponsor
Azienda Ospedaliero, Universitaria Pisana — full company profile →
Who can join
Adults 18 to 80, any sex, with Perianal Fistula. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to evaluate the efficacy of the local injection of autologous micro-fragmented adipose tissue obtained with the Lipogems®system in patients with trans-sphincteric fistulas untreatable with fistulotomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03913910
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lipogems
Trials testing the same drug.
- NCT05594862 — Treatment of Crohn's Complex Perianal Fistulas With Tissue Transplantation by Local Injection of Micro-fragmented Autolo · NA · active not recruiting
- NCT04274543 — Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military · Phase 2 · completed
- NCT04136743 — Ultrasound-Guided Treatments for Shoulder Pain in Wheelchair Users With Spinal Cord Injury · Phase 2 · unknown
- NCT03714659 — Autologous, Micro-fragmented Adipose Tissue for Meniscal Tears · Phase 2 · completed
- NCT03555773 — Micro-fragmented Adipose Tissue and Complex Crohns' Anal Fistulas · NA · completed
Other recruiting trials for Perianal Fistula
Currently open trials in the same condition.
- NCT07519850 — The Impact of Perianal Disease on Patient's Sex Life · recruiting
- NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
- NCT06446635 — Semiflex Assisted Vacuum Therapy for Perianal Abscesses/Sinuses and Fistula: a Pilot Study · NA · recruiting
Other Azienda Ospedaliero, Universitaria Pisana trials
Trials by the same sponsor.
- NCT07512453 — Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration · not yet recruiting
- NCT06333132 — Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat) · NA · unknown
- NCT07250607 — Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications · active not recruiting
- NCT07132086 — Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting · completed
- NCT06876948 — NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencep · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03913910 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero, Universitaria Pisana
- Last refreshed: 14 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913910.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing